Scancell Holdings (SCLP) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 Sep 2024 07:00 AM
RNS
Notice of Final Results
17 Sep 2024 07:00 AM
RNS
Strategic Partnership with PharmaJet
02 Sep 2024 07:00 AM
RNS
Scancell to attend upcoming conferences
30 Jul 2024 07:17 AM
RNS
Scancell Appoints Dr Nermeen Varawalla as CMO
30 Jul 2024 07:00 AM
RNS
Scancell Appoints Dr Nermeen Varawalla as CMO
24 Jul 2024 07:00 AM
RNS
Update from iSCIB1+ Clinical Advisory Meeting
10 Jul 2024 07:00 AM
RNS
Appointment of Dr Florian Reinaud to the Board
02 Jul 2024 07:00 AM
RNS
Extension of Convertible Loan Notes
01 Jul 2024 07:00 AM
RNS
Block Listing Return and Total Voting Rights
21 Jun 2024 07:00 AM
RNS
Change of Nominated Advisor
12 Jun 2024 07:32 AM
RNS
Agreement with major biotech
31 May 2024 07:00 AM
RNS
Scancell to attend upcoming conferences
30 May 2024 07:00 AM
RNS
Update on ModiFY trial
24 May 2024 07:00 AM
RNS
Scancell to present at ASCO Annual Meeting
21 May 2024 07:00 AM
RNS
Issue of share options
16 May 2024 07:00 AM
RNS
Presenting at the Sachs 10th Annual Oncology Forum
09 May 2024 07:00 AM
RNS
Scancell presenting at 21st CIMT Annual Meeting
17 Apr 2024 07:00 AM
RNS
Presenting at the Annual Immuno-Oncology Summit
16 Apr 2024 07:00 AM
RNS
Block Listing Six Monthly Return
03 Apr 2024 07:00 AM
RNS
Employee exercise of share options
02 Apr 2024 07:00 AM
RNS
Scancell to Present at 2024 AACR Annual Meeting
28 Mar 2024 01:21 PM
RNS
Scancell Appoints WG as Joint Broker
26 Mar 2024 12:22 PM
RNS
First iSCIB1+ patient dosed
14 Mar 2024 11:17 AM
RNS
Appointment of Sath Nirmalananthan to the Board
12 Mar 2024 07:00 AM
RNS
Scancell Attendance at Upcoming Conferences
04 Mar 2024 07:00 AM
RNS
Presenting at Next-Gen Immuno-Oncology Conference
20 Feb 2024 07:00 AM
RNS
Change of Auditor
05 Feb 2024 07:00 AM
RNS
Directorate Change
30 Jan 2024 07:00 AM
RNS
Interim Results
26 Jan 2024 07:00 AM
RNS
Notice of Interim Results and Presentation
17 Jan 2024 01:46 PM
RNS
Update on SCOPE trial
28 Dec 2023 05:36 PM
RNS
Holding(s) in Company
27 Dec 2023 11:38 AM
RNS
Holding(s) in Company
19 Dec 2023 07:00 AM
RNS
Result of the Open Offer
06 Dec 2023 12:41 PM
RNS
PDMR Notification
01 Dec 2023 07:00 AM
RNS
Results of Placing
30 Nov 2023 05:03 PM
RNS
Proposed Capital Raise to raise approximately £6m
29 Nov 2023 02:35 PM
RNS
Result of AGM
28 Nov 2023 07:00 AM
RNS
Update on SCOPE trial
10 Nov 2023 08:32 AM
RNS
Scancell to present at 20th SMR Congress
01 Nov 2023 07:00 AM
RNS
Scancell to present at 38th Annual SITC meeting
31 Oct 2023 12:00 PM
RNS
Notice of AGM
31 Oct 2023 07:00 AM
RNS
Results for the Year Ended 30 April 2023
20 Oct 2023 07:00 AM
RNS
Update on Final Results
18 Oct 2023 07:00 AM
RNS
Scancell to speak at World Vaccine Congress Europe
17 Oct 2023 07:00 AM
RNS
Block Listing Six Monthly Return
11 Oct 2023 07:00 AM
RNS
Change of Date for Final Results
03 Oct 2023 07:00 AM
RNS
Notice of Final Results and Investor Presentation
19 Sep 2023 07:00 AM
RNS
Positive data from Phase 2 SCOPE trial with SCIB1
14 Sep 2023 07:00 AM
RNS
Scancell to present three posters at ICI

Scancell Holdings PLC is a biopharmaceutical company that develops vaccines and other therapies to treat cancer and infectious diseases. Scancell's research focuses on the human immune system and how to use it to develop new treatments. Scancell uses four technology platforms to develop its products: ImmunoBody, Moditope, GlyMab and AvidiMab.

Scancell was founded in 1997 based on research led by Professor Lindy Durrant at the University of Nottingham.

Scancell Holdings PLC is listed on the London Stock Exchange (LSE) as SCLP.

Scancell share price listed at 8p in 2010.

UK 100

Latest directors dealings